Details for New Drug Application (NDA): 203078
✉ Email this page to a colleague
NDA 203078 describes CISATRACURIUM BESYLATE, which is a drug marketed by Accord Hlthcare, Caplin, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly, Hengrui Pharma, Hikma, Hospira, Meitheal, Piramal, Piramal Critical, Sagent Pharms Inc, Sandoz Inc, Somerset, Zydus Pharms, and Somerset Theraps Llc, and is included in twenty-eight NDAs. It is available from sixteen suppliers. Additional details are available on the CISATRACURIUM BESYLATE profile page.
The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
Summary for 203078
| Tradename: | CISATRACURIUM BESYLATE |
| Applicant: | Hikma |
| Ingredient: | cisatracurium besylate |
| Patents: | 0 |
Pharmacology for NDA: 203078
| Physiological Effect | Neuromuscular Nondepolarizing Blockade |
Suppliers and Packaging for NDA: 203078
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CISATRACURIUM BESYLATE | cisatracurium besylate | INJECTABLE;INJECTION | 203078 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9396 | 0143-9396-01 | 1 VIAL in 1 CARTON (0143-9396-01) / 5 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2MG BASE/ML | ||||
| Approval Date: | Jun 28, 2022 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 10MG BASE/ML | ||||
| Approval Date: | Dec 18, 2023 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
